Drug profile · INN
ipratropium
ATROVENT
ipratropium (ATROVENT) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Cipla Australia Pty Ltd.
TGA: approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — ipratropium
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.81
Quick answer
ipratropium (ATROVENT) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Cipla Australia Pty Ltd.
Key facts
INN ipratropium
Brand ATROVENT
Mechanism Muscarinic acetylcholine receptor M3 antagonist
Originator Cipla Australia Pty Ltd
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Pipeline programs
Frequently asked questions
What is ipratropium?
ipratropium (ATROVENT) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Cipla Australia Pty Ltd.
What is the brand name for ipratropium?
ATROVENT is a marketed brand name for ipratropium. Check FDA Drugs@FDA for the current US label holder and prescribing information.